MiMedx Group Inc
NASDAQ:MDXG
MiMedx Group Inc
Income from Continuing Operations
MiMedx Group Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MiMedx Group Inc
NASDAQ:MDXG
|
Income from Continuing Operations
$97.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
59%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.3B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$479m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-28%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$4.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
-$535.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.4B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
MiMedx Group Inc
Glance View
MiMedx Group Inc. is a fascinating player in the realm of life sciences, operating at the dynamic intersection of biotechnology and tissue engineering. Nestled in the healthcare sector, MiMedx specializes in developing and distributing regenerative biomaterials and allografts derived from human amniotic tissue. This niche focus allows the company to tap into the potential of natural biologics to promote effective healing and enhance patient outcomes, particularly in chronic and complex wound care. Their product offerings, which primarily include amniotic membrane and umbilical cord products, are harnessed to aid in tissue repair and to reduce inflammation and scarring, all of which are critical elements in successful clinical treatment. In terms of revenue generation, MiMedx's business model revolves around an intricate balance of innovation and strategic partnerships. By meticulously refining their proprietary processing techniques, the company maintains a competitive advantage that appeals to healthcare providers across various specialties, including orthopedics, podiatry, and reconstructive surgery. Revenue streams are predominantly driven by the sale of these biotechnology innovations to hospitals, healthcare providers, and through direct distribution channels. Further enhancing their financial robustness, MiMedx invests in extensive clinical trials and research, which underpin their marketing and educational efforts to broaden the adoption of their products. With a keen eye on developing medical solutions that cater to an aging population and a growing demand for effective wound care products, MiMedx positions itself as a crucial innovator in its sector.
See Also
What is MiMedx Group Inc's Income from Continuing Operations?
Income from Continuing Operations
97.2m
USD
Based on the financial report for Sep 30, 2024, MiMedx Group Inc's Income from Continuing Operations amounts to 97.2m USD.
What is MiMedx Group Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
59%
Over the last year, the Income from Continuing Operations growth was 2 141%.
You don't have any saved screeners yet